Vor Biopharma Inc
Research Vor Biopharma Inc (VOR) on Bullrun: market cap USD 1.31B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerVOR
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 1.31B
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 883.08M
- Free cash flow-USD 150.65M
Valuation Snapshot
latest market cap is USD 1.31B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 695.98M | -USD 143.65M | n/a | -70.5 | USD 396.49M | USD 3.00M | -USD 164.31M |
| FY2024 | USD 0 | -USD 116.91M | -USD 99.89M | n/a | -34.03 | USD 81.95M | USD 31.83M | -USD 96.66M |
| FY2023 | n/a | -USD 117.86M | -USD 101.36M | n/a | -1.75 | USD 31.36M | USD 35.66M | USD 150.72M |
| FY2022 | n/a | -USD 92.09M | -USD 93.61M | n/a | -2.33 | USD 57.71M | USD 38.91M | USD 250.61M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 1.31B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 89.48M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 138.50M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 152.56M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 436.57M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 431.96M | n/a | n/a | n/a |
About Vor Biopharma Inc
Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy. It has a license agreement with RemeGen Co., Ltd. for the exploitation, development, and commercialization of telitacicpet and related products.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Vor Biopharma Inc's market cap?
Vor Biopharma Inc's market capitalization is USD 1.31B.
What does Vor Biopharma Inc do?
Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy. It has a license agreement with RemeGen Co., Ltd. for the exploitation, development, and commercialization of telitacicpet and related products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.